REGN logo Regeneron Pharmaceuticals +
Regeneron Pharmaceuticals
+

Regeneron Pharmaceuticals (REGN) Business News

Track Regeneron Pharmaceuticals in real time with a live news feed covering Regeneron Pharmaceuticals stock news, official press releases, company announcements, and an archive of historical Regeneron Pharmaceuticals news. ...more

  • Calendar
    Years
    Get instant access
    Sign up for free
    Get instant access
    Sign up for free
    Month
    Jan
    Feb
    Mar
    Apr
    May
    Jun
    Jul
    Aug
    Sep
    Oct
    Nov
    Dec
    Date
    Su
    Mo
    Tu
    We
    Th
    Fr
    Sa
    Selected Filter
    No selection
9:42 AM | Monday | Sep 7, 2026 GlobeNewsWire

REGN Investors Have Opportunity to Lead Regeneron Pharmaceuticals, Inc. Securities Fraud Lawsuit with SBS Law

NEW News Thumbnail
4:51 AM | Monday | Sep 7, 2026 Defense World

California State Teachers Retirement System Purchases 97,569,482 Shares of Regeneron Pharmaceuticals, Inc. $REGN

NEW News Thumbnail
12:00 PM | Sunday | Sep 6, 2026 GlobeNewsWire

Bronstein, Gewirtz & Grossman LLC Urges Regeneron Pharmaceuticals, Inc. Investors to Act: Class Action Filed Alleging Investor Harm

News Thumbnail
7:43 AM | Sunday | Sep 6, 2026 Newsfile Corp

REGN UPCOMING DEADLINE: Faruqi & Faruqi, LLP Reminds Regeneron (REGN) Investors of Securities Class Action Lawsuit Deadline on September 14, 2026

News Thumbnail
4:36 AM | Saturday | Sep 5, 2026 Defense World

AlphaGrep UK Ltd Purchases Shares of 1,943 Regeneron Pharmaceuticals, Inc. $REGN

News Thumbnail
3:44 AM | Saturday | Sep 5, 2026 Defense World

B. Metzler seel. Sohn & Co. AG Grows Stock Position in Regeneron Pharmaceuticals, Inc. $REGN

News Thumbnail
11:10 AM | Friday | Sep 4, 2026 Business Wire

SEPTEMBER 14, 2026 REGN INVESTOR DEADLINE: Regeneron Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit, Robbins Geller Rudman & Dowd LLP Announces

News Thumbnail
9:37 AM | Friday | Sep 4, 2026 Newsfile Corp

REGN 10-DAY DEADLINE ALERT: Regeneron Pharmaceuticals, Inc. Investors Alerted to September 14, 2026 Lead Plaintiff Deadline in Class Action Lawsuit

News Thumbnail
9:28 AM | Friday | Sep 4, 2026 Newsfile Corp

REGN DEADLINE NOTICE: Faruqi & Faruqi, LLP Reminds Regeneron (REGN) Investors of Securities Class Action Lawsuit Deadline on September 14, 2026

News Thumbnail
11:00 AM | Thursday | Sep 3, 2026 GuruFocus

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of EyePoint, Inc. - EYPT

News Thumbnail

REGN Investors Have Opportunity to Lead Regeneron Pharmaceuticals, Inc. Securities Fraud Lawsuit with SBS Law

GlobeNewsWire

9:42 AM | Monday | Sep 7, 2026

news photo
Loading...

LOS ANGELES, Sept. 07, 2026 (GLOBE NEWSWIRE) -- Schall, Brown & Schwartz LLP (“SBS”), a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Regeneron Pharmaceuticals, Inc. (“Regeneron” or “the Company”) (NASDAQ: REGN) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.

Read full article redirect
9:42 AM | Monday | Sep 7, 2026

REGN Investors Have Opportunity to Lead Regeneron Pharmaceuticals, Inc. Securities Fraud Lawsuit with SBS Law

GlobeNewsWire

LOS ANGELES, Sept. 07, 2026 (GLOBE NEWSWIRE) -- Schall, Brown & Schwartz LLP (“SBS”), a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Regeneron Pharmaceuticals, Inc. (“Regeneron” or “the Company”) (NASDAQ: REGN) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.

Read full article arrow
NEW News Thumbnail
4:51 AM | Monday | Sep 7, 2026

California State Teachers Retirement System Purchases 97,569,482 Shares of Regeneron Pharmaceuticals, Inc. $REGN

Defense World

California State Teachers Retirement System increased its position in Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) by 63,274.2% in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 97,723,683 shares of the biopharmaceutical company's stock after purchasing an additional 97,569,482 shares during the

Read full article arrow
NEW News Thumbnail
12:00 PM | Sunday | Sep 6, 2026

Bronstein, Gewirtz & Grossman LLC Urges Regeneron Pharmaceuticals, Inc. Investors to Act: Class Action Filed Alleging Investor Harm

GlobeNewsWire

NEW YORK, Sept. 06, 2026 (GLOBE NEWSWIRE) -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized investor-rights law firm, announces that a class action lawsuit has been filed against Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and certain of its officers.

Read full article arrow
News Thumbnail
7:43 AM | Sunday | Sep 6, 2026

REGN UPCOMING DEADLINE: Faruqi & Faruqi, LLP Reminds Regeneron (REGN) Investors of Securities Class Action Lawsuit Deadline on September 14, 2026

Newsfile Corp

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Regeneron To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in Regeneron between August 1, 2025 and May 15, 2026 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] New York, New York--(Newsfile Corp. - September 6, 2026) - Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Regeneron Pharmaceuticals, Inc. ("Regeneron" or the "Company") (NASDAQ: REGN) and reminds investors of the September 14, 2026 deadline to seek the role of lead plaintiff in a federal securities class action that has been... Read more

Read full article arrow
News Thumbnail
4:36 AM | Saturday | Sep 5, 2026

AlphaGrep UK Ltd Purchases Shares of 1,943 Regeneron Pharmaceuticals, Inc. $REGN

Defense World

AlphaGrep UK Ltd acquired a new position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) in the undefined quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 1,943 shares of the biopharmaceutical company's stock, valued at approximately $1,212,000. Regeneron Pharmaceuticals comprises 0.4% of AlphaGrep

Read full article arrow
News Thumbnail
3:44 AM | Saturday | Sep 5, 2026

B. Metzler seel. Sohn & Co. AG Grows Stock Position in Regeneron Pharmaceuticals, Inc. $REGN

Defense World

B. Metzler seel. Sohn and Co. AG grew its holdings in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) by 37.
5% during the undefined quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 4,472 shares of the biopharmaceutical company's stock after purchasing an

Read full article arrow
News Thumbnail
11:10 AM | Friday | Sep 4, 2026

SEPTEMBER 14, 2026 REGN INVESTOR DEADLINE: Regeneron Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit, Robbins Geller Rudman & Dowd LLP Announces

Business Wire

SAN DIEGO--(BUSINESS WIRE)---- $REGN #REGN--The case alleges Regeneron and its top executives made false and/or misleading statements to investors.

Read full article arrow
News Thumbnail
9:37 AM | Friday | Sep 4, 2026

REGN 10-DAY DEADLINE ALERT: Regeneron Pharmaceuticals, Inc. Investors Alerted to September 14, 2026 Lead Plaintiff Deadline in Class Action Lawsuit

Newsfile Corp

San Francisco, California--(Newsfile Corp. - September 4, 2026) - Hagens Berman Sobol Shapiro LLP alerts investors in Regeneron Pharmaceuticals (NASDAQ: REGN) that a securities class action lawsuit has been filed after its surprising revelations concerning a Phase 3 clinical trial of a therapy intended to treat patients with melanoma. The news that the trial failed drove the price of Regeneron shares sharply lower and, along with the severe market reaction ($11 billion market cap wipeout), triggered the lawsuit which seeks to represent investors who purchased or otherwise acquired shares of Regeneron common stock between August 1, 2025 and May 15, 2026.

Read full article arrow
News Thumbnail
9:28 AM | Friday | Sep 4, 2026

REGN DEADLINE NOTICE: Faruqi & Faruqi, LLP Reminds Regeneron (REGN) Investors of Securities Class Action Lawsuit Deadline on September 14, 2026

Newsfile Corp

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Regeneron To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in Regeneron between August 1, 2025 and May 15, 2026 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] New York, New York--(Newsfile Corp. - September 4, 2026) - Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Regeneron Pharmaceuticals, Inc. ("Regeneron" or the "Company") (NASDAQ: REGN) and reminds investors of the September 14, 2026 deadline to seek the role of lead plaintiff in a federal securities class action that has been... Read more

Read full article arrow
News Thumbnail
11:00 AM | Thursday | Sep 3, 2026

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of EyePoint, Inc. - EYPT

GuruFocus

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of EyePoint, Inc. - EYPT PR Newswire

Read full article arrow
News Thumbnail